Literature DB >> 18224386

Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version).

Masafumi Kurosumi1, Sadako Akashi-Tanaka, Futoshi Akiyama, Yoshifumi Komoike, Hirofumi Mukai, Seigo Nakamura, Hitoshi Tsuda.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18224386     DOI： 10.1007/s12282-007-0016-x

Source DB:  PubMed          Journal:  Breast Cancer        ISSN： 1340-6868            Impact factor:   4.239


× No keyword cloud information.
  34 in total

1.  Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy.

Authors:  Takayoshi Uematsu; Masako Kasami; Sachiko Yuen
Journal:  Eur Radiol       Date:  2010-05-09       Impact factor: 5.315

2.  18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response.

Authors:  Shigeto Ueda; Toshiaki Saeki; Takashi Shigekawa; Jiro Omata; Tomoyuki Moriya; Junji Yamamoto; Akihiko Osaki; Nobuko Fujiuchi; Misono Misumi; Hideki Takeuchi; Takaki Sakurai; Hitoshi Tsuda; Katsumi Tamura; Jiro Ishida; Yoshiyuki Abe; Etsuko Imabayashi; Ichiei Kuji; Hiroshi Matsuda
Journal:  Int J Clin Oncol       Date:  2011-08-10       Impact factor: 3.402

3.  High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy.

Authors:  Tomo Osako; Rie Horii; Masaaki Matsuura; Kaoru Domoto; Yoshimi Ide; Yumi Miyagi; Shunji Takahashi; Yoshinori Ito; Takuji Iwase; Futoshi Akiyama
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-09       Impact factor: 4.553

4.  Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer.

Authors:  Haruko Hiraike; Osamu Wada-Hiraike; Shunsuke Nakagawa; Shigehira Saji; Daichi Maeda; Yuichiro Miyamoto; Kenbun Sone; Michihiro Tanikawa; Katsutoshi Oda; Keiichi Nakagawa; Tetsu Yano; Masashi Fukayama; Yuji Taketani
Journal:  Exp Ther Med       Date:  2011-08-12       Impact factor: 2.447

5.  Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.

Authors:  Kazuhiro Kitajima; Koya Nakatani; Kazushige Yamaguchi; Masatoyo Nakajo; Atsushi Tani; Mana Ishibashi; Keiko Hosoya; Takahiro Morita; Takayuki Kinoshita; Hayato Kaida; Yasuo Miyoshi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-12       Impact factor: 9.236

6.  Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer.

Authors:  Yuji Hayashi; Hiroyuki Takei; Satoshi Nozu; Yoshihiro Tochigi; Akihiro Ichikawa; Naoki Kobayashi; Masafumi Kurosumi; Kenichi Inoue; Takashi Yoshida; Shigenori E Nagai; Hanako Oba; Toshio Tabei; Jun Horiguchi; Izumi Takeyoshi
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

7.  Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer.

Authors:  Motoi Baba; Masato Takahashi; Katsushige Yamashiro; Hideki Yokoo; Moto Fukai; Masanori Sato; Mitsuchika Hosoda; Toshiya Kamiyama; Akinobu Taketomi; Hiroko Yamashita
Journal:  Surg Today       Date:  2015-10-22       Impact factor: 2.549

8.  Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature.

Authors:  Takayoshi Kiba; Nao Morii; Hirotoshi Takahashi; Shinji Ozaki; Misao Atsumi; Fumi Masumoto; Hiroyasu Yamashiro
Journal:  Oncol Lett       Date:  2016-03-16       Impact factor: 2.967

9.  A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).

Authors:  Kenjiro Aogi; Toshiaki Saeki; Seigo Nakamura; Masahiro Kashiwaba; Nobuaki Sato; Norikazu Masuda; Yoshiaki Rai; Shinji Ohno; Katsumasa Kuroi; Reiki Nishimura; Keiko Miyakoda; Futoshi Akiyama; Masafumi Kurosumi; Tadashi Ikeda
Journal:  Int J Clin Oncol       Date:  2012-07-26       Impact factor: 3.402

10.  Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapy.

Authors:  Mitsuhiro Hayashi; Kazuharu Kai; Yasuhiro Okumura; Tomofumi Osako; Nobuyuki Arima; Hirotaka Iwase; Reiki Nishimura
Journal:  Oncol Lett       Date:  2011-01-11       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.